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Abstract
Bacterial resistance to conventional antibiotics is a global threat that has spurred the devel-
opment of antimicrobial peptides (AMPs) and their mimetics as novel anti-infective agents.
While the bioavailability of AMPs is often reduced due to protease activity, the non-natural
structure of AMPmimetics renders them robust to proteolytic degradation, thus offering a
distinct advantage for their clinical application. We explore the therapeutic potential of N-
substituted glycines, or peptoids, as AMP mimics using a multi-faceted approach that
includes in silico, in vitro, and in vivo techniques. We report a new QSAR model that we
developed based on 27 diverse peptoid sequences, which accurately correlates antimicro-
bial peptoid structure with antimicrobial activity. We have identified a number of peptoids
that have potent, broad-spectrum in vitro activity against multi-drug resistant bacterial
strains. Lastly, using a murine model of invasive S. aureus infection, we demonstrate that
one of the best candidate peptoids at 4 mg/kg significantly reduces with a two-log order the
bacterial counts compared with saline-treated controls. Taken together, our results demon-
strate the promising therapeutic potential of peptoids as antimicrobial agents.
Introduction
Drug development in the golden age of antibiotics (the 1960s and 1970s) resulted in an unprec-
edented ability to control infections worldwide. However, initial successes bred a false sense of
security that modern medicine could retain complete control over bacterial infections [1]. The
emergence and re-emergence of multi-drug resistant (MDR) bacteria has since been recognized
as an alarming threat to public health, and a dearth of novel antibiotic classes is creating
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significant unmet clinical need [2, 3]. Most new antibiotics are closely related in structure to
existing ones, making the route to pathogen development of drug resistance short and inevita-
ble [2]. The pharmaceutical industry’s waning interest in antibiotic development coupled with
the inadequate management of existing drugs are additional factors contributing to the urgency
of this global crisis [4, 5]. Among the most notable new and promising classes of broad spec-
trum antibiotic agents are the antimicrobial peptides (AMPs) and their mimics.
AMPs, also known as host defense peptides, are key components of innate immunity that
have recently generated significant interest as innovative lead compounds for clinical use [6, 7].
While AMPs comprise a family of molecules diverse in source, length, and structure, these pep-
tides are typically short (12 to 50 amino acids), carry a net positive charge (+ 2 to 9), and contain
up to 50% hydrophobic amino acids [8]. These physicochemical properties permit interactions
with microbial membranes and enable their typically broad-spectrum antimicrobial activity
either by directly disrupting the membrane or permeabilizing it and acting on intracellular tar-
gets, ultimately causing cell death [9, 10]. Some cationic AMPs appear to interact with the polya-
nionic surface of lipopolysaccharide (LPS), destabilizing the outer membrane [11–13] before
passing through by self-promoted uptake to the cytoplasmic membrane. It is unlikely that any
class of antibiotic agents can entirely thwart the development of resistant bacterial strains [14–
16], but it is clear that the non-receptor mediated and generalized mode of action employed by
AMPs can be more robust to bacterial resistance than conventional antibiotics [10].
While the use of cationic antimicrobial peptides has met with some success [17], several
recent clinical trials have failed to show efficacy for certain AMPs [10]. Statistically significant
activity has been demonstrated for only one candidate peptide, MX-226, for treatment of topi-
cal infections. An issue limiting the applicability of AMP drugs is their susceptibility to protease
activity, which can lead to an unfavorable pharmacokinetic profile and low bioavailability [10].
One approach to achieving selective, broad-spectrum antimicrobial activity through a general-
ized mode of action while avoiding protease susceptibility is the use of peptidomimetic, non-
natural scaffolds [18, 19]. N-substituted glycines, or peptoids, are sequence-specific synthetic
oligomers that can be designed to mimic the helical, cationic, and amphipathic structure of
some AMPs. Certain peptoids have been shown to exhibit potent and selective antimicrobial
activity and appear to employ mechanisms of action similar to those of their natural counter-
parts [20–24]. Peptoids are based on a backbone structure that is identical to that of peptides,
however peptoid side chains are appended to the amide nitrogens rather than the α-carbons
[25]. This modification has important structural implications. The achiral backbone structure
of peptoids precludes backbone hydrogen bonding, but they can be induced to form stable
polyproline type-I-like helices by the incorporation of bulky, α-chiral side chains [25–30].
Here we report a study that both extends the analogy between peptide and peptoid mecha-
nisms of action, and demonstrates the proof-of-concept in vivo efficacy of peptoids against
MDR pathogenic bacterial strains, with comparison to the activities of related peptides. The
antimicrobial activities of peptoid-based AMP mimics is studied here using a multi-faceted
approach that incorporates in silico, in vitro, and in vivo techniques. We have generated a
library of short, helical peptoids that mimic classical amphipathic antimicrobial helical pep-
tides, and incorporated selected previously reported peptoid sequences that have diverse struc-
tures, antimicrobial potencies, and cell selectivities [20, 21] into a QSAR (quantitative structure
activity relationship) model using chemical descriptors [31]. As was previously shown for pep-
tides [31], the QSAR model was able to accurately predict the minimum inhibitory concentra-
tion (MIC) of an excluded peptoid based on its structure. The in vitro antibacterial activity of a
selected set of peptoids was evaluated against 20 pathogenic and multi-drug resistant bacterial
strains in comparison to that of two clinically relevant antimicrobial peptides and four broad-
spectrum, clinically utilized antibiotics. Several peptoids exhibited potency superior to that of
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comparator peptides and antibiotics against both Gram-negative and Gram positive-strains.
An LPS binding assay was used to demonstrate that peptoid 1 was able to interact with the
polyanionic component of Gram-negative bacteria to an extent similar to that of peptides.
Lastly a proof-of-concept study using an invasive Staphylococcus aureus challenge model dem-
onstrated the ability of peptoid 1 to achieve a statistically significant reduction of bacterial
counts in vivo compared to a saline-treated control group.
Materials and Methods
Peptoid and peptide synthesis and purification
The peptoids were synthesized on an ABI 433 peptide synthesizer using the submonomer
method [25] on Rink amide MBHA resin. Briefly, bromoacetic acid activated by diisopropyl-
carbodiimide is used to form a bromoacetylated intermediate on a terminal secondary amine
group. Bromine is then substituted with the desired primary amine through an SN2 displace-
ment, to build the peptoid chain. The synthesized peptoids were cleaved from the resin using
trifluoroacetic-acid:triisopropylsilane:water (95:2.5:2.5, v:v:v) for 10 minutes. The peptoids
were purified by reversed-phase HPLC using a C18 column and a linear acetonitrile/water
(0.1% trifluoroacetic acid) gradient of 5%–95% acetonitrile over 45 minutes. Final purity was
greater than 98% and correct molecular identity was verified using electrospray ion mass spec-
trometry. The control peptides were synthesized using solid phase Fmoc chemistry, purified to
purity> 95% using reversed phase HPLC, and were analyzed by mass spectrometry by Gen-
Script (Piscataway, NJ, USA).
Antimicrobial testing against superbug strains
The MICs of test agents were measured using a modified broth micro-dilution method in Difco
Mueller Hinton medium [32], on a panel of bacterial pathogens that were both susceptible and
resistant to common antibiotics (S1 File). Briefly, serial dilutions were performed in 0.01% acetic
acid containing 0.2% bovine serum albumin at 10-fold the desired final concentration. Ten μL
of the 10-fold concentrated test reagents were added to each well of a 96-well polypropylene
microtitre plate containing 90 μL of Mueller Hinton media per well. Bacteria were added to the
plate from an overnight culture at a final concentration of 2–7 x 105 CFU/mL and incubated
overnight at 37°C. The MIC is defined as the concentration at which no growth was observed.
QSARmodeling
QSAR descriptors were calculated using Molecular Operating Environment v2006.05 (Chemi-
cal Computation Group Inc., Montereal, Canada). A total of 233 descriptors were initially cal-
culated based on a three-dimensional structure estimated from energy minimization using the
generalized Born solvation model. A linear equation for predicting activity based on QSAR
descriptors was constructed in two phases. First, a set of up to ten descriptors were chosen that
gave the highest cross-validated regression between predicted and measured activity where
activity was taken as the log10 of the MIC in molarity. Descriptors were considered in order of
declining regression against activity (i.e. the first descriptor had the highest absolute correlation
with activity; the next descriptor had the next highest). Initially, each descriptor was considered
individually in a linear regression; the descriptor with the highest performance (described
below) was selected. Next, the linear regression models were constructed using the previously
identified descriptor with an additional term using each other descriptor. The model with high-
est performance with two descriptors was selected. This process was repeated for up to ten
descriptors or until no improvements were found for additional descriptors.
Peptoid Antimicrobials
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Performance of the multiple regression models was calculated as the absolute correlation of
the predicted to measured activity using a 10-fold cross-validation. For a 10-fold cross-valida-
tion, the data were randomly selected into ten sets. Nine of the ten sets were used to construct
the multiple linear regression model; the model was then used to predict the activity of the set
that was not used. By repeating the process for each set, predictions of activity were made for
each peptoid without using that peptoid data itself in constructing the model.
In the second phase, a linear regression model was constructed for all peptoid data using
only the descriptors identified. The standard errors and p-values of each parameter in the
model were calculated. Where a p-value of a parameter was less than 0.1, the parameter was
dropped and the model evaluated with the remaining descriptors. Parameters were dropped
until all remaining descriptors had P-values> 0.1.
Dansyl polymyxin B displacement assay
The Dansyl polymyxin B (DPX) displacement assay was carried out as described earlier [33,
34]. In brief, the fluorescence of DPX (Invitrogen) bound to LPS (P. aeruginosa) was measured
by using a Luminescence spectrometer LS 50B (Perkin Elmer) with excitation and emission-
wavelengths of 340 nm and 485 nm, respectively. A predetermined amount of DPX, resulting
in 90% saturation of LPS, was added to 1 mL of 3 μg/mL of purified LPS. Small aliquots (5 μL
of 1 μg/mL) of test compounds were added under constant stirring in the cuvette, and the dis-
placement of DPX was measured for 30–60 seconds as a decrease in fluorescence. The process
was repeated until maximum displacement was reached.
Murine model of bacterial infection
Animal experiments were performed in accordance with University of British Columbia Care
Ethics Committee approval and guidelines as per animal care certificate #A04-0020. Female
CD1 mice (6–8 week old) were weighed, marked, and injected with 200 μL of S. aureus (ATCC
25923) ~109 CFU/mouse suspended in Mueller Hinton broth containing 5% mucin and
injected intraperitoneally. Four hours after infection, animals were treated with 4 mg/kg or
100μg per mouse of peptoid 1 (experimental group; n = 10) or an equivalent volume of saline
(control group; n = 10). All animals were monitored two hours after each injection step, they
were also evaluated at the end of the working day and the next morning a couple of hours prior
to the experimental endpoint. Humane endpoints criteria; immobilization and shaking, were
put down but none of the test subjects were evaluated to reach these endpoints prior to the
experimental endpoint. The mice were euthanized 24 hours post-infection using CO2. The
peritoneal cavity was exposed and washed with 5 mL PBS. The lavage was diluted to 10−5 in log
order increments and spotted in duplicate onto Mueller Hinton agar plates. Plates were incu-
bated overnight at 37°C and colonies were counted the following day. One animal in the saline
treated control group was reported dead the morning after the infection, likely due to the infec-
tion load. This animal was assigned the highest colony forming unit count obtained in the
experiment. The statistical differences between peptide treated and naïve mice were assessed
using PRISM1 (GraphPad Software Inc., San Diego, CA) using contingency tables Chi-square
test, with a confidence interval of 99%.
Results
QSARmodel
We incorporated a select group of previously reported peptoid sequences with a broad range of
physicochemical properties, antimicrobial potencies, and cell selectivities into a QSAR analysis
Peptoid Antimicrobials
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capable of modeling the structural basis of peptoid antibacterial activity. All peptoid sequences
were derived from the parent dodecamer, peptoid 1 (20), which is composed of 1/3 lysine-like,
positively charged monomers (NLys) and 2/3 phenylalanine-like hydrophobic, aromatic
monomers (Nspe) with the repeating sequence H-(NLys-Nspe-Nspe)4-NH (Fig 1A, Table 1).
A computer simulation of the three-dimensional structure of peptoid 1 based on energy mini-
mization (S1 File). All Peptoid sequences are summarized in Table 1 and the chemical struc-
tures of the side chains are shown in Fig 1B. Table 1 also summarizes the broad range of
activities demonstrated by this library of compounds exhibited in the screening assays against
B. subtilis, E. coli, erythrocytes (HD10/HD50), and NIH 3T3 cells. The peptoids demonstrate
good selectivity for bacterial membranes over erytorcytes, however in parallel they do show an
interesting and surprising inhibitory effect on the metabolism of the NIH 3T3 cells.
The model was built based on antibacterial activity measurements against only E. coli
(ATCC 35218), excluding only the parent sequence, peptoid 1. Against E. coli, these
sequences ranged from potent (MIC ~ 6.3 uM) to inactive (> 100 uM). The three-dimen-
sional structures of the peptoids were projected, and a total of 233 descriptors that were avail-
able in MOE (Molecular Operating Environment) were calculated. In addition, we created
descriptors that were the products of these 233 MOE descriptors, resulting in a set of 27,494
descriptors. Of these, the majority did not vary between the peptoids or were highly corre-
lated (Pearson correlation>0.95 or <-0.95) and thus eliminated, resulting in a total of 916
descriptors for modeling.
The most important descriptors for explaining activity were identified using multiple linear
regression models. Ten descriptors were identified that yielded the highest regression in a
10-fold cross-validation, in which 90% of the data was modeled and used to predict the activi-
ties of the remaining 10% a total of 10 times. These descriptors were then combined to con-
struct a multiple linear regression model, shown in Fig 2. The activity of the excluded peptoid 1
was then predicted (calculated) to be 7.0 μM against E. coli, using this QSAR model based on
the equations illustrated in Fig 2. This predicted activity is remarkably similar to the measured
value (6.3 μM), demonstrating the accuracy of the QSAR model and creating a solid foundation
for the future optimization and design of peptoid-based AMP mimics.
Broad-spectrum antibacterial peptoid activity
The antimicrobial activities of a subset of peptoids with varying characteristics and activities
were further tested against 20 multi-drug resistant (MDR), clinically relevant pathogens (Tables
2 and 3, S1 File). MSI-78 [35] and MX-226 [36], two widely studied and clinically-investigated
AMPs, as well as four commonly used antibiotics (the aminoglycoside tobramycin, the fluoro-
quinolone ciprofloxacin, the carbapenem β-lactam imipenem, and the cephalosporin ceftazi-
dime) [31] were included in this study to provide a basis of comparison to other classes of
antimicrobial agents. MX-226, also known as Omiganan1 (Migenix, Inc., Vancouver, British
Columbia, Canada), is an indolicidin derivative that is currently being developed to reduce the
incidence of device-related infections. In Phase III clinical trails, the topical application of MX-
226 pentahydrocloride in a 1% gel (Omigard) led to a significant, 21% reduction of colonization
of central venous catheters, and a 50% reduction in tunnel infections (www.migenix.com/prod_
226.html) [36, 37]. MSI-78 (pexiganan) is a 22-amino acid analogue of the peptide magainin-2,
which was first developed by Magainin Pharmaceuticals Inc. (now Genaera; http://www.
genaera.com), and was clinically tested for efficacy in the treatment of diabetic foot ulcers. Phase
III clinical trials showed that MSI-78 eliminated or significantly reduced infection in over 90%
of patients while exhibiting a favorable toxicity profile, yet FDA approval was denied in 1999
because improved efficacy above standard treatment could not be demonstrated [37].
Peptoid Antimicrobials
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Fig 1. Chemical structures of (A) peptoid 1 and (B) the peptoid monomers.
doi:10.1371/journal.pone.0135961.g001
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Out of the 19 tested peptoids, 14 compounds demonstrated extremely broad-spectrum
activity. In general, the activity against multi-drug resistant strains was highly correlated with
those observed in the preliminary screen against E. coli; only certain clinically isolated Pseudo-
monas strains appeared to be intrinsically resistant to most of the tested peptoids. Peptoid 1
was found to be highly potent against 19 of the 20 bacterial strains tested and compared
Table 1. Characteristics of antimicrobial peptoids, screened for activity againstB. subtilis and E. coli bacterial strains.











Peptoid 1 1819 H-(NLys-Nspe-Nspe)4-NH2 1.6 6.3 21/100 5.1 65.1 [20,
21]
1scr 1819 H-(Nspe)2-(NLys-Nspe)3-(Nspe)3-NLys-NH2 1.6 6.3 64/>200 8.5 61.1
1-NLys5,11 1753 H-(NLys-Nspe-Nspe-NLys-NLys-Nspe)2-NH2 0.78 50 >100 /
>100
85 51.2














0.78 > 100 >200 /
>200
40 50.8
16mer 918 H-(NLys-Nspe-Nspe)2-NH2 > 100 > 100 ND ND 41.0 [20,
21]
19mer 1379 H-(NLys-Nspe-Nspe)3-NH2 1.6 25 ND ND 46.0 [20,
21]
111mer 1658 H-(NLys-Nspe-Nspe)3-NLys-Nspe-NH2 0.78 6.3 103 /
>200
11 ND
1-Pro3 1755 H-NLys-Nspe-L-Pro-(NLys-Nspe-Nspe)3-NH2 1.6 12.5 74 / >200 12 63.0
1-Pro6 1755 H-NLys-Nspe2-NLys-Nspe-L-Pro-(NLys-
Nspe2)2-NH2
1.6 12.5 83 / >200 18 62.4 [20]
1-Pro9 1755 H-(NLys-Nspe2)2-NLys-Nspe-L-Pro-(NLys-
Nspe2)-NH2
1.6 12.5 165 /
>200
24 62.6
1-Nrpe3,6,9,12 1819 H-(NLys-Nspe-Nrpe)4-NH2 1.6 6.3 16 / 67 3.8 63.5
1ach 1701 H-(NLys-Npm-Npm)4-NH2 1.6 12.5 183 /
>200
16 59.8
1ach-Nspe2 1721 H-(NLys-Nspe-Npm)- (NLys-Npm-Npm)3-NH2 0.78 6.3 160 /
>200
11 60.8
1ach-Nspe12 1721 H-(NLys-Npm-Npm)3-(NLys-Npm-Nspe)-NH2 1.6 6.3 164 /
>200
15 62.0
1-Npm2,3,8,9 1763 H-(NLys-Npm-Npm-NLys-Nspe-Nspe)2-NH2 1.6 6.3 39 / >200 15 63.3
1-Npm2,5,8,11 1763 H-(NLys-Npm-Nspe)4-NH2 1.6 6.3 87 / >200 6.8 63.6
1-Nsdpall 1547 H-(NLys-Nsdp-Nsdp)4-NH2 0.78 25 >200 /
>200
64 63.2
1-Nsdp2,3,8,9 1683 H-(NLys-Nsdp-Nsdp-NLys-Nspe-Nspe)2-NH2 0.78 12.5 77 / >200 19 64.7
1-Nsdp2.5.8.11 1683 H-(NLys-Nsdp-Nspe)4-NH2 0.78 12.5 111 /
>200
20 63.8
1-Nsna6,12 1919 H-(NLys-Nspe-Nspe-NLys-Nspe-Nsna)2-NH2 1.6 50 ND ND 53.0 [20,
21]
Minimal inhibitory concentration test of B. subtilis ATCC 6633 and E. coli ATCC 35218. HD10/HD50 representing the hemolytic activity of the tested
peptoids. The dose found to inhibit the metabolic activity of NIH 3T3 cells using the colorimetric tetrazolium salt based MTS assay is reported as the ID50
(inhibitory dose). HPLC elution is reported as the average percentage of acetonitrile (ACN) in the solvent mixture upon compound elution for three
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Fig 2. Model for predicting peptoid antimicrobial activity against Gram-negative E. coli. (a) gives an overview of the ten descriptors contributing the
most to the predictive model. (b) gives the equation for calculating the predicted MIC (log10[MIC molar]) activity for any given peptoid, using the products of
the descriptors in given as V,W, X, Y and Z, being (PEOE_VSA_FPPOS x Q_VSA_FNEG), (PEOE_VSA_plus2 x Q_RPC_plus), (Q_VSA_FPOL x
FASA_H), (E_nb x glob) and (VAdjEq x SMR_VSA3), respectively (calculated separately for the specific peptoid). (c) The equation uses factors a, b, c, d and
e, estimated contribution for each of the descriptor product elements, the accuracy and preciseness for a, b, c, d and e are indicated with standard error and
p-values, and (d) the constant factors for centering and scaling of V,W, X, Y, Z and theMIC activities (forming the basis for the predictive model). (e)
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favorably to that of MX-226; the MICs of peptoid 1 ranged from 2 to 16 μg/mL, while those of
MX-226 ranged from 16 to 256 μg/mL. Interestingly, the isolate that was most resistant to pep-
toid 1 was an MDR P. aeruginosa that was also polymyxin B resistant (MIC 64 μg/mL) due to
overexpression of the PhoPQ and PmrAB 2-component regulators and downstream arn LPS-
modification operon [38]. The potency of MSI-78 was approximately equal to that of peptoid 1
against P. aeruginosa, P.maltophilia, and E. cloacae; however, peptoid 1 demonstrated superior
potency against two Gram-negative isolates and all Gram-positive strains, S. aureus, E. faecalis,
and E. faecium. Against all Gram-positive strains tested, the MICs of peptoid 1 ranged from
2–8 μg/mL (median of 2 μg/mL), while those of MSI-78 ranged from 4–256 μg/mL (median of
16 μg/mL). These results suggest that peptoid 1 could be a promising candidate to treat some
of the most recalcitrant and dangerous human infections.
LPS binding activity of peptoid 1
Wemeasured the LPS binding activity of peptoid 1 and comparator AMPs in order to investi-
gate the nature of the interactions of these compounds with the outer membrane of Gram-neg-
ative species. The outer membrane of Gram-negative bacteria not only serves as a physical
barrier to external stresses, but also provides structural integrity and plays a major role in the
host’s immune response as a major antigen and the primary intrinsic (endo)toxin of Gram-
negative bacteria, contributing to sepsis [11]. LPS is a polyanionic glycolipid, and is the major
lipid component found within the outer surface layer of the Gram-negative bacterial outer
membrane. LPS has divalent cationic binding sites that are stabilized and partially neutralized
by divalent cations such as Mg2+ and Ca2+; such interactions contribute to outer membrane
stability. Through the process of self-promoted uptake [39, 40], cationic peptides are able to
displace divalent cations, disrupting LPS cross-bridging and destabilizing the outer membrane,
in a process that promotes enhanced influx of the peptides.
The fluorescently labeled lipopeptide dansyl polymyxin B (DPX) has been shown to bind
strongly to LPS, and this binding result in an enhanced fluorescence of the dansyl group [33].
The ability of other cationic molecules to displace DPX molecules bound to LPS (monitored by
reduction in fluorescence) assesses their relative ability to bind to LPS [33, 34]. While the
highly cationic MSI-78 (+10 charge) displaced 100% of bound DPX (equivalent to that of poly-
myxin B), peptoid 1 and MX-226 displaced 71% and 73% of bound DPX, respectively. These
results correlate well with previous work, which demonstrated that a variety of polycations
were able to displace between 63% and 100% of bound DPX [33]. A second parameter charac-
terizing the LPS/polycation interaction is the I50, which is defined as the concentration of a
polycation that displaces 50% of LPS-bound DPX. The I50 is inversely related to the relative
affinity of each molecule for binding sites on LPS. For these compounds, I50 results indicated
the order of decreasing LPS affinity as follows: MSI-78 (I50 = 1.4 μM)> Peptoid 1 (I50 =
2.6 μM)> polymyxin B (I50 = 3.2 μM)>MX-226 (I50 = 5.0 μM).
In vivo biocompatibility and S. aureus clearance of peptoid 1
This dosage was selected to be on the conservative end of the dosage range typically evaluated
for AMPs (1 mg/kg to 24 mg/kg) in other animal studies [35, 41, 42]. To screen for acute signs
of toxicity, three healthy mice were injected intraperitoneally with 4 mg/kg (100 μg per mouse)
of peptoid 1, and a second control group with an equivalent volume of saline. At the conclusion
of the 24 hours post-injection observation period, all mice appeared to be healthy and exhibited
normal activity and no weight loss or abject morbidity (decreased movement, abnormal gait,
piloerection, isolation in cage, or hunched abdomen).
Peptoid Antimicrobials
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We utilized an established murine model of invasive bacterial infection [41] to investigate
the in vivo efficacy of peptoid 1 to treat an infection with S. aureus, a leading cause of nosoco-
mial infections. The data in Fig 3 shows that bacterial counts in the peritoneal lavage fluid were
significantly reduced (p< 0.0001) in mice treated with peptoid 1, compared to saline-treated
controls.
Discussion
We leveraged the breadth in activities demonstrated by these peptoids to build a QSAR model
capable of modeling the structural basis of peptoid antimicrobial activity. Much work has been
invested in developing robust QSAR solutions for predicting the antimicrobial activities of syn-
thetic AMPs [43, 44]. The transfer of experience and knowledge from this work has allowed us
to build a fairly precise model, which appears to accurately predict peptoid antibacterial activ-
ity, based on the analysis of a set of structurally diverse peptoids (Fig 1). Investigating the
nature of the ten chemical descriptors used in this presented model, it is apparent that the six
most influential descriptors all are directly linked to peptoid charge (partial charge or confor-
mational dependent charge) (Fig 2a). These are all sophisticated charge measurements inter-
preting the charge distribution over the entire chemical structure, and not just a simple net
charge estimate summarizing the number of charge side chains. This is in good accordance
with observation from other structure activity studies on AMP [31, 44–46], indicating that the
Fig 3. In vivo efficacy of peptoid 1. Four hours after intraperitoneal i.p. challenge with methicillin susceptible S. aureus, peptoid 1 was administered locally
at a concentration of 4 mg/kg. Colony forming units (CFU) in the peritoneal lavage fluid from individual mice (plated in duplicate) at 24 hours are shown in the
vehicle (saline) and peptoid 1 treatment groups. The graph indicates the geometric mean of each group. Dead animals at 24 hours were assigned the highest
colony count observed in the experiment. *** indicates P<0.0001 by contingency Chi-square analysis, with a confidence interval of 99%.
doi:10.1371/journal.pone.0135961.g003
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antibacterial mechanism of action of AMPs and peptoids might be founded on the same princi-
ples. The four last descriptors in the model are related to molecular shape, surface area, and
potential energy, suggesting that peptoid antimicrobial activity is also affected by molecular
size. These results demonstrate the impact that computational techniques can have on poten-
tially streamlining the rational design of potent antimicrobial peptoids in the future.
A subset of the peptoid library was tested side-by-side with two comparator antimicrobial
peptides, for their activities against a panel of the most pathogenic, multi-drug resistant strains,
including both Gram-negative (13 strains) and Gram-positive (7 strains) species. The MICs
determined for antimicrobial peptides MX-226 and MSI-78 were consistent with previously
reported values for these compounds against a similar panel of species [35, 37]. The broad-
spectrum activity profile of peptoid 1 was found to be superior to those of the other peptoids,
and to both MSI-78 and MX-226. The MIC of peptoid 1 8 μg/mL for 19 out of the 20 patho-
gens tested; this was the case for only 12 of 20 organisms for MSI-78 and none of 20 for MX-
226. Interestingly, MSI-78 and peptoid 1 showed similar activities against most Gram-negative
strains, but MSI-78 was found to have reduced activity against most of the Gram-positive
strains (MRSA and VRE). The MICs of peptoid 1 (2–16 μg/mL) were generally about 10-fold
lower than those of MX-226 (16–256 μg/mL), demonstrating the superior in vitro antimicro-
bial activity of peptoid 1. While it has been shown that in vitro activity and in vivo efficacy are
not always directly correlated [41, 47], the potent, broad-spectrum activity of peptoid 1 against
multi-drug-resistant bacterial cultures is a very encouraging result.
LPS affinity was studied to understand in greater detail the probable initial interactions of
peptoid 1 with the outer surface of Gram-negative bacteria. The reduced competitiveness of
peptoid 1 and MX-226 for sites on LPS (71% and 73% displacement, respectively) compared
to that of MSI-78 and polymyxin B (100% displacement) suggests that all sites are not equally
accessible to all cationic molecules [33]. Several properties of the cationic molecules that may
influence their binding affinities for diverse sites on LPS include molecular size, net charge,
hydrophobicity, and overall steric bulk, as well as specific molecular structure. The relative
competitiveness of these molecules, however, does not translate directly into their relative
affinity for LPS, a property that is inversely related to the I50. While both MSI-78 (I50 =
1.4 μM) and peptoid 1 (I50 = 2.6 μM) had stronger affinity for LPS than polymyxin B (I50 =
3.2 μM), MX-226 (I50 = 5.0 μM) demonstrated a weaker affinity. All of the cationic molecules
tested have greater affinity for LPS than the most common cell envelope divalent cation, Mg2+
(620 μM) [48], suggesting that they can all initially displace Mg2+ and bind to the outer mem-
brane. Interestingly, peptoid 1 and MSI-78 had the best activity against Gram-negative bacte-
ria (Table 2) and also the highest LPS binding affinity. This correlation is reasonable, since the
LPS binding affinity of other polycations correlates well with their ability to permeabilize
outer membranes [33].
While LPS binding affinity is not necessarily synonymous with endotoxin neutralizing
activity [49, 50], the strong LPS binding of peptoid 1 is also a promising result that encourages
further studies. LPS is one of the primary causes of sepsis, a serious condition that affects many
hospital patients [35]. Gram-negative bacteria in septic patients release LPS, which initiates a
cascade of pro-inflammatory events. Many endotoxemia treatments have been investigated,
including polymyxin B and a variety of cationic peptides [51]. In a clinical study, polymyxin
B immobilized on a surface was shown to improve the survival rates of moderately septic
patients, but was ineffective in patients with severe sepsis [52]. MSI-78 was found to not only
reduce endotoxin plasma levels in a rat model of sepsis, but also to reduce bacterial counts by
four orders of magnitude using the caecal ligation and puncture model of bowel perforation
and sepsis [35]. The strong LPS binding affinity of peptoid 1 suggests that it could be a candi-
date anti-sepsis molecule.
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Lastly, we studied the ability of peptoid 1 to treat an infection in vivo using a murine model
of invasive S. aureus bacterial challenge. At a concentration of 4 mg/kg, peptoid 1 apparently
caused no medium-term toxicity; treatment at this concentration resulted in an average two-
log order reduction in bacterial counts in the peritonium. Moreover, mortality was reduced by
75% in the peptoid 1-treated group compared to saline-treated controls. While other groups
have published in vivo results with several types of non-natural AMP mimetics [42, 53, 54],
this is the first report of bacterial count reduction after treatment with a helical peptoid-based
AMP mimetic in vivo. This encouraging proof-of-concept result with peptoid 1 could usher in
a new era in the development of peptoids as a class of clinically useful antimicrobial agents.
Several lines of study that warrant further investigation include (1) optimal peptoid design for
in vivo efficacy and safety; (2) optimal dosage and full toxicity profile; (3) the efficacy of peptoid
treatment compared to AMP treatment; (4) the ability to treat a polyclonal infection using an
animal sepsis model [35], and (5) the metabolic fate of peptoid-based antimicrobial agents.
In summary, this study was designed to combine the power of in silico, in vitro, and in vivo
techniques to probe the therapeutic potential of peptoids as a new class of antimicrobial agents.
The QSAR modeling results not only underscore the analogous behavior of peptoids and
AMPs, but also demonstrate the utility of computer models to facilitate the design of future
generations of peptoids. In vitro results suggested that peptoid 1 has potent antimicrobial activ-
ities against a range of Gram-positive and Gram-negative strains, which is apparently superior
to those of comparator AMPs and overall better against Superbug organisms than four of the
most highly used conventional antibiotics in our society. The relatively strong affinity of pep-
toid 1 for anionic binding sites on LPS suggest that it can displace stabilizing divalent cations
and permeabilize the outer membrane of Gram-negative bacteria through self-promoted
uptake. Most importantly, we present evidence that peptoid 1 can reduce colony forming units
and mortality compared to a saline-treated control group in a murine model of invasive S.
aureus challenge. Taken together, these results underscore the promising therapeutic potential
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